Background The aim of this study was to elucidate whether genetic screening test results of pediatric patients with steroidresistant nephrotic syndrome (SRNS) vary with ethnicity. Methods Using high-throughput DNA sequencing, 28 nephrotic syndrome-related genes were analyzed in 110 children affected by SRNS and 10 children with isolated proteinuria enrolled by 5 centers in China (67 boys, 53 girls). Their age at disease onset ranged from 1 day to 208 months (median, 48.8 months). Patients were excluded if their age at onset of disease was over 18 years or if they were diagnosed as having Alport syndrome. Results A genetic etiology was identified in 28.3% of our cohort and the likelihood of establishing a genetic diagnosis decreased as the age at onset of nephrotic syndrome increased. The most common mutated genes were ADCK4 (6.67%), NPHS1 (5.83%), WT1 (5.83%), and NPHS2 (3.33%), and the difference in the frequencies of ADCK4 and NPHS2 mutations between this study and a study on monogenic causes of SRNS in the largest international cohort of 1,783 different families was significant. A case of congenital nephrotic syndrome was attributed to a homozygous missense mutation in ADCK4, and a de novo missense mutation in TRPC6 was detected in a case of infantile nephrotic syndrome. Conclusions Our results showed that, in the first and the largest multicenter cohort of Chinese pediatric SRNS reported to date, ADCK4 is the most common causative gene, whereas there is a low prevalence of NPHS2 mutations. Our data indicated that the genetic testing results for pediatric SRNS patients vary with different ethnicities, and this information will help to improve management of the disease in clinical practice.
Introduction
In childhood, the most common form of nephrotic syndrome (NS), characterized by massive proteinuria, hypoalbuminemia, edema, and hyperlipidemia, is idiopathic NS. Most children with idiopathic NS are steroid-responsive and have a favorable outcome. However, approximately 10∼20% of the children with idiopathic NS do not respond to steroid therapy, called steroid-resistant NS (SRNS), and 20∼40% of these patients progress to end-stage renal disease (ESRD) [1] [2] [3] [4] [5] . Focal segmental glomerulosclerosis (FSGS) is most frequently seen in SRNS. Advances in molecular genetics have revealed that a considerable proportion of cases with SRNS are caused by single-gene mutations, leading to profound podocyte dysfunction, and these cases are usually also resistant to immunosuppressive agents [6, 7] . Therefore, in clinical practice, it is important to identify patients with genetic causes of SRNS to provide personalized therapy.
To date, there have been approximately 30 genes known to cause SRNS and/or FSGS with autosomal recessive, autosomal dominant, and X-linked recessive modes of inheritance, and genetic SRNS can be isolated or syndromic [8] [9] [10] [11] . Because of the heterogeneous nature of SRNS, several mutated gene prioritization strategies have been developed based on age at onset, family history, or renal histology [8, 12, 13] . However, genetic testing using the conventional Sanger method is quite laborious and expensive. To simultaneously screen multiple genes related to SRNS/FSGS, some recent studies have shown that targeted next generation sequencing (NGS) is a cost-effective strategy, allowing for a more complete characterization of correlations between genotype and phenotype and between genotype and treatment responses [7, [14] [15] [16] [17] . However, it is not clear whether the frequencies of damaged alleles vary among different ethnicities in children with SRNS, which influences the strategy for genetic testing. The aim of the present study was to elucidate whether the genetic testing results of pediatric SRNS vary with ethnicity.
Materials and methods

Patients
The patients were recruited between 2012 and 2014 by pediatric nephrologists from 5 centers in China (2 in eastern China, 1 in southern China, 1 in central China, and 1 in northern China) based on fulfillment of one of the following two criteria: steroid-resistant idiopathic NS (including those cases occurring in the first year of life), and proteinuria with FSGS or a positive family history of proteinuria. Patients were excluded if their age at onset of disease was over 18 years, or if they were diagnosed with Alport syndrome (based on meeting at least one of the following four criteria:
1. Abnormal staining of the type IV collagen α5 chain in the epidermal basement membrane 2. Abnormal staining of type IV collagen α chains in the glomerular basement membrane 3. Mutations of COL4A3, COL4A4, or COL4A5 4. Ultrastructural changes in the glomerular basement membrane typical of Alport syndrome . The procedures were approved by the ethics committees of the 5 centers. After receiving informed consent from the patients or their family members, blood samples and comprehensive clinical data were collected and analyzed. When available, relatives' DNA samples were obtained. Nephrotic syndrome was defined by urinary protein excretion ≥50 mg/kg per 24 h or urine protein/creatinine > 3 mg/mg with hypoalbuminemia. Steroid resistance was defined by persistent proteinuria after 8 weeks of daily 2 mg/kg prednisone treatment (maximum dose 60 mg/day). Patients with a positive family history of proteinuria and/or renal failure were defined as familial cases, otherwise patients were defined as sporadic cases.
Targeted NGS and data analyses
Using a QIAamp DNA Blood Mini Kit (Qiagen), genomic DNA was isolated from peripheral blood leukocytes in all participants. Using the Nimblegen SeqCap EZ Choice system, targeted sequencing capture DNA probes were designed for exons and the flanking 30 bp intronic sequences of 28 known NS genes (ADCK4, ARHGDIA, CD2AP, CFH, COQ2,  COQ6, CUBN, DGKE, ITGA3, ITGB4, LAMB2, MEFV,  MYO1E, NPHS1, NPHS2, PDSS2, PLCE1, PTPRO,  SCARB2, SMARCAL1, TTC21B, ACTN4, ARHGAP24,  INF2, LMX1B, PAX2, TRPC6 , and WT1). Targeted sequencing was performed on the HiSeq2000 or Hiseq2500 platform (Illumina) as paired end 100-bp reads (PE100) by BGITianjin, China.
Image analyses, error estimation, and base calling were performed using the Illumina Pipeline (version 1.3.4) to generate the primary sequence data. Low-quality reads and potential adaptor contaminations were removed from the primary data using a local algorithm. The clean short reads were mapped to the human genome (hg19) using BWA software (Burrows Wheeler Aligner http://sourceforge.net/projects/biobwa/). SOAPsnp software (http://soap.genomics.org.cn/) and SAM tools Pileup software (http://sourceforge.net/projects/ samtools/) were used to detect single nucleotide variants and small insertion and deletions respectively. Copy number variants (CNV) were identified by using a BGI in-house pipeline called batCNV1.0. All variants were annotated using a BGIannotation pipeline developed in-house (available on demand).
Variants with support reads <10 and a ratio <10% were removed, and variants with a minor allele frequency ≥ 1% in the control database such as NCBI dbSNP build141 (http:// www.ncbi.nlm.nih.gov/SNP/), 1000 Genomes Project (http:// www.1000genomes.org/), Exome sequencing project (ESP6500. http://evs.gs.washington.edu/EVS/), Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute. org/) and BGI in-house database, were filtered out as polymorphisms. The functional significance of unpublished variants was predicted using SIFT, PolyPhen 2, and Condel. When no prediction scores were available, Mutation Taster was used. Splice site effect prediction was performed using Human Splicing Finder (Version 3.0). The evolutionary conservation of the variant sites was evaluated using the PhyloP Primates tool. Variants were interpreted based on standards recommended by the American College of Medical Genetics and Genomics (ACMG) [18, 19] .
In addition to being consistent with the reported inheritance pattern, the candidate variants were considered diseasecausing based on meeting at least one of the following criteria:
1. Truncating mutations (nonsense, obligatory splice site, and frameshift) 2. Variants previously described as causing disease in a patient with a similar phenotype 3. Amino acid substitutions that exhibited high evolutionary conservation (PhyloP Primates Score >1.5) and two of four prediction scores classified the allele as causing disease: SIFT, Mutation Taster, PolyPhen 2 prediction Humvar score 0.8-1, or Condel score >0.5.
Validation of disease-causing mutations and segregation analysis
All disease-causing mutations identified with NGS were confirmed in probands by conventional PCR and Sanger sequencing using an ABI 3730XL automatic sequencer (SinoGenoMax, China), and segregation analyses was performed for firstdegree relatives whenever their DNA was available.
As parental DNA samples were unavailable, segregation analyses were performed with molecular cloning followed by Sanger sequencing of relevant clones in one patient with compound heterozygous missense variants in SMARCAL1 (the protocol and primer information are available upon request).
Results
A total of 120 unrelated patients (67 men, 53 women), from 24 provinces, municipalities, and autonomous regions in China, were included. Almost all were of Han Chinese ethnicity, with one patient from Uighur. Their median age at disease onset was 48.8 months old (range 1 day to 208 months). Of these patients, 110 patients were diagnosed with SRNS, and 10 patients had isolated proteinuria. The clinical characteristics are summarized in Table 1 .
Gene analysis
Forty-two functionally significant mutations in 10 of the 28 targeted genes, including 20 missense, 11 nonsense, 8 splice sites, and 3 small insertions, were identified in 34 of the 120 patients, giving a mutation detection rate of 28.3%. Of the 42 mutations identified, 25 (59.5%) were novel, and the remaining 17 mutations had been reported elsewhere [12, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . None of the 34 patients were from consanguineous families, whereas 35.3% of them (12 patients) had a positive family history of proteinuria, and 2.9% (1 patient) had a positive family history of renal failure. Pathogenic mutations were detected in 68.4% of 19 familial patients (13 patients) and 23.6% of 89 sporadic patients (21 patients). Of 24 patients harboring disease-causing mutations in recessive NS genes, homozygous mutations were found in 6 patients and compound heterozygous mutations were found in 18 patients. A description of all the detected pathogenic mutations and the clinical phenotypes of the patients are given in Tables 2, 3 and  Supplemental Table 1 .
In patients with disease onset before the age of 13 years, the likelihood of establishing a genetic diagnosis decreased as the age at onset for NS increased (Fig. 1) . We detected the diseasecausing mutation in 75% of children in the first 3 months of life, 27.8% at the age of 4-12 months, 25.9% between the aged of 13 months and 5 years, and 14.7% at the age 6-12 years. Meanwhile, the distribution of the detected causative genes according to age at onset of NS is given in Table 4 and Fig. 1 . Mutations in NPHS1, WT1, LAMB2, and PLCE1 were responsible for 12 out of the 30 patients (40%) with NS onset within the first year of life, and NPHS1 was the most frequent causative gene. Mutations in ADCK4 and TRPC6, but not NPHS2, were also responsible for this form of SRNS. WT1 mutations were detected in 7 of the 84 patients (8.3%) of NS with onset within 5 years, which could be used to help diagnose Denys-Drash syndrome in patients 25 and 27, Frasier syndrome in patients 33 and 35, and isolated NS in patients 3, 77, and 78. ADCK4 was the most frequent genetic basis for pediatric SRNS, especially for SRNS with onset at age 6-12 years (14.7%).
Sadowski et al. [16] published the results of monogenic causes of SRNS in the largest international cohort of 1,783 different families (2,016 individuals). We therefore compared the mutation detection rate and most common causative genes in Sadowski's study and our study. Except for the NEIL1 gene, the targeted NGS panel used by the present study included genes analyzed in Sadowski's study and two additional genes (TTC21B and PAX2). The top 3 frequently mutated genes in Sadowski's study were NPHS2 (9.93%. 95% CI = 8.58∼11.41%), NPHS1 (7.34%. 95% CI =6.18∼8.66%), and WT1 (4.77%. 95% CI =3.83∼5.86%), whereas ADCK4 was the least common mutated gene (0.17%. 95% CI =0.03∼0.5%). In our study, the most common mutated genes were ADCK4 (6.67%. 95% CI =2.92∼12.71%), NPHS1 (5.83%. 95% CI =2.38∼11.65%), WT1 (5.83%. 95% CI =2.38∼11.65%), and NPHS2 (3.33%, 95% CI =0.92∼8.31%). The difference in the frequencies of ADCK4 and NPHS2 mutations between these two studies was significant (no overlap of the 95% CI between different studies was considered significant, p < 0.05).
Renal biopsy
Seventy-nine of the 120 patients (65.8%) underwent renal biopsy (Tables 1, 5 ), and 42 patients had FSGS. Genetic alterations were found in 12 of the 42 patients with FSGS (28.6%) and 3 of the 7 patients with mesangioproliferative glomerulonephritis. Of 34 patients with a single-gene cause, 17 patients underwent renal biopsy, and diffuse mesangial sclerosis was not observed (Table 5) .
Genotypic and phenotypic features of ADCK4-related nephropathy ADCK4 was the most common mutated gene in our study; thus, we analyzed its genotypic and phenotypic characteristics. Five missense mutations (including two previously reported mutations) and two nonsense mutations were identified in 8 patients.
The missense mutation p. Asp250His was found in 5 patients, either in the homozygous state (patients 4 and 30) or in compound heterozygosity with another mutation on the second allele (patients 83, 117, and 16). The age at first feature identified in these patients ranged from 10 days to 9.2 years, with an average age of 5 years. Patients 83, 117, 4, and 30 presented with SRNS, whereas patient 16 presented only with proteinuria. Patients 83, 117, and 30 developed ESRD at age the 11.7 years, 11 years, and 6 years respectively, whereas patient 16 had normal renal function at the age of 12 years. FSGS was diagnosed in patients 83, 30, and 16, and sclerosing glomerulonephritis was diagnosed in patient 117.
Patients 82 and 120 were homozygous for the novel missense mutation p.Ser246Asn. Patient 82 manifested SRNS at age 8.2 years, with renal histology showing FSGS, and patient 120 had proteinuria at the age of 17.3 years, with the renal biopsy revealing mild mesangial proliferative glomerulonephritis. Both of these patients had a normal renal function after a 1-year follow up. The older brother of patient 82 had ESRD and proteinuria (3+) at the age of 11 years, and renal ultrasound examination revealed renal atrophy. He died after 4 months of dialysis. Her parents and a younger brother, who carried heterozygous p.Ser246Asn, had no renal symptoms. The older brother of patient 120 had ESRD and proteinuria (3+) at the age of 21 years, and a renal ultrasound examination showed renal atrophy. He underwent kidney transplantation with their mother as the donor. His kidney function was stable on immunosuppressive drugs at 1 year after transplantation. Segregation analyses showed that he was also homozygous for p.Ser246Asn. The healthy father carried heterozygous p.Ser246Asn, but the mother's blood sample was not available.
Patient 119 was a compound heterozygote for p.Glu81* from his mother and p.Arg490Cys from his father. He presented with steroid-resistant nephrotic-level proteinuria at the age of 11 years, with the renal biopsy showing FSGS. His renal function was within the normal range at the age of 12 years. The serum C3 levels of him and his father were 0.446 g/L and 0.371 g/L (normal range 0.6∼1.5 g/L) respectively. Their serum C4 levels were normal and his parents had no renal manifestations.
Discussion
The application of genetic testing in pediatric SRNS has significant implications for the comprehensive management of this disease. Therefore, the present study, by simultaneously screening 28 NS-related genes, characterized the molecular spectrum in the first and largest multicenter cohort of Chinese pediatric SRNS patients reported to date. The most important finding is that Chinese pediatric SRNS patients are genetically different, with the ADCK4 gene shown to be important.
We identified pathogenic mutations in 28.3% of our cohort, which was very close to the highest previous mutation detection rate in the largest international cohort of SRNS (mutations were detected in 31.2% of families with SRNS manifesting before the age of 18 years) [16] . As in children of other ethnicities with SRNS, the percentage of detecting diseasecausing mutations decreased as the age at onset of NS increased in the present study [12, 16, 17] . However, three genotypic features in our series were found:
1. No NPHS2 mutations were detected in congenital or infantile NS, which was consistent with the results of Japanese and Korean pediatric SRNS populations [20, 36] , and contrary to the results in other reports [12, 16, 17, 37] . A homozygous missense mutation in ADCK4 was identified in a patient with congenital NS, and a de novo missense mutation in TRPC6 was detected in a patient with infantile NS. To our knowledge, these patients are the youngest individuals with disease caused by ADCK4 and TRPC6 mutations. Both findings emphasized the necessity to include ADCK4 and TRPC6, but not NPHS2, in the mutation analysis of NS in the 1st year of life, in addition to NPHS1, WT1, LAMB2, and PLCE1. 2. Mutations in NPHS2 were detected less frequently in the present study than in the largest international cohort of SRNS (3.33% vs 9.93%) and in smaller series of pediatric SRNS (3.33% vs 4.5% to 40%) [12, 16, 27, 38, 39] . Furthermore, no NPHS2 mutations were detected in our previous study [40] and in 18 African-American children with SRNS [41] , whereas a rate of 9.1% NPHS2 [42] . In contrast to the low frequency of NPHS2 mutations, a surprisingly higher mutation rate of ADCK4 (6.67%) was observed in our series [16, 29, 43] . Therefore, for the genetic diagnosis of SRNS with an age at onset over 1 year, we suggest that when NGS technology is not available, the first step should be to screen for ADCK4. 3. We only detected NPHS1 and WT1 mutations in patients with an age at onset within the 1st year and at 5 years respectively, whereas a considerable fraction of the largest international cohort of SRNS presenting before the age of 18 years was found to have mutations in these two genes [16] , and in Lipska's study, WT1 mutations accounted for 3.9% of 227 nonsyndromic SRNS patients with onset of age between 10 and 20 years [44] . All the above differences in genetic results between this study and previous studies, especially the study of the largest international cohort of SRNS, indicated that a small study size may reduce the chance of detecting causative gene mutations, and ethnic differences exist in the frequencies of damaging alleles.
Previously, ADCK4-related glomerulopathy was identified in 0.17-3.7% of SRNS patients, the disease first presented mostly in 10-to 20-year-old patients, and FSGS/global glomerulosclerosis was observed in all biopsied patients [16, 29, 30, 43] . However, in this study, the ADCK4 mutation detection rate was 6.67%, and the age at first feature identified was mostly 6-11 years. In addition to FSGS and global glomerulosclerosis, mesangial proliferative glomerulonephritis was also observed. Similar to previously reported cases with ADCK4 mutations [29, 30] , onset with different levels of proteinuria was observed in our cohort, and progression to ESRD could occur before the age of 10 years. These findings demonstrated the heterogeneous renal phenotype of ADCK4 disease.
This study also had some limitations. First, our cohort was not large. However, study participants in the present study were from 24 out of 34 provinces, municipalities, autonomous regions and special administrative regions in China and were enrolled by five centers located in eastern China, southern China, central China, and northern China. To our knowledge, it was the largest multicenter cohort of Chinese pediatric SRNS reported to date, which could balance the sampling bias. Second, patients with ADCK4 or CUBN mutations may be amenable to supplementation with coenzyme Q10 or vitamin B12. However, in our cohort, 4 patients progressed to ESRD before genetic diagnosis, and 6 patients were lost to follow-up at the time of genetic diagnosis. Thus, there was no chance to observe the effect of treatment with coenzyme Q10 or vitamin B12. Third, there were no data on extrarenal manifestations in 19 of the 34 patients (55.9%) with causative mutations, and renal biopsy was less frequently performed in our subjects with an onset before 5 years; therefore, it was difficult to delineate the causative gene-associated phenotype and the association of genotype with histopathological diagnoses completely.
In conclusion, we found that in Chinese pediatric SRNS patients, ADCK4 is the most frequent causative gene, whereas there is a low prevalence of NPHS2 mutations, and infantileonset nephrotic syndrome can be caused by the TRPC6 mutation. Our data indicated that the genetic screening strategy of pediatric SRNS should vary with ethnicities, which will help to improve management of the disease during clinical practice and provide a valuable reference for genetic testing among different ethnic or racial populations.
